New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine
Moderna said the shot reduced flu cases by 27% in a 40,000-person study and won accelerated approval for seniors.
- In WASHINGTON, The FDA approved Moderna's new flu vaccine for adults age 50 or older, marking the first use of Nobel Prize-winning mRNA technology for influenza immunization.
- Vaccines developed with Nobel Prize-winning mRNA technology offer faster production timelines than traditional methods, enabling Moderna to adapt quickly if the flu virus mutates.
- A study of 40,000 people aged 50 to 64 found the vaccine reduced flu cases by about 27%, while The FDA granted accelerated approval for people 65 or older.
- Following a public dispute earlier this year involving Health Secretary Robert Kennedy and The FDA, Moderna expects the vaccine available soon at select retailers.
- While the shot caused temporary reactions like injection site pain, Moderna data showed no major safety issues, providing a new option for Americans ahead of fall vaccination season.
12 Articles
12 Articles
The US Food and Drug Administration (FDA) has approved a new type of flu vaccine for the elderly, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, the manufacturer Moderna said.
New kind of flu shot is on the way as FDA approves Moderna’s mRNA-based vaccine
It's the flu shot to be made with the same technology as the COVID vaccine.
New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine
The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic.
You can get the vaccine free of charge from your local health center.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium










